XELOX stop-and-go trial:A phase 2 study of 1st line chemotherapy for unresectable or recurrent colorectal cancer.

XELOX stop-and-go trial:A phase 2 study of 1st line chemotherapy for unresectable or recurrent colorectal cancer. - FMOG1001 XELOX stop and Go

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005191

Enrollment

Registered

2011-03-06

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable or recurrent colorectal cancer

Interventions

XELOX therapy 6 courses, followed by XELODA 6 courses, then XELOX

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: From 25 to 75 years old, colorectal cancer, PS 0-1, chemotherapy naive, proper organ function, not indicated for bevacizumab for some reasons.

Exclusion criteria

Exclusion criteria: Double cancer, severe allergic history, active infections, severe complications

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Secondary

Measure	Time frame
Response rate Time to treatment failure Overall survival Safety plofiles(Rate of Grade 3 neurotoxicity, adverse events)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026